Suppr超能文献

化疗药物紫杉醇介导 NLRP3 炎性小体的激活预刺激。

Chemotherapeutic Agent Paclitaxel Mediates Priming of NLRP3 Inflammasome Activation.

机构信息

Department of Microbiology and Immunology, Institute for Immunology and Immunological Diseases, Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul, South Korea.

BK 21 PLUS Project Team, Laboratory Animal Medicine, College of Veterinary Medicine, Chonnam National University, Gwangju, South Korea.

出版信息

Front Immunol. 2019 May 16;10:1108. doi: 10.3389/fimmu.2019.01108. eCollection 2019.

Abstract

Paclitaxel is a chemotherapeutic drug commonly used to treat different types of cancer. In addition to its antitumor effect, paclitaxel is also known to promote Toll-like receptor (TLR) 4-dependent inflammatory responses, which may lower its chemotherapeutic efficacy. However, it remains unclear whether paclitaxel is able to affect inflammasome signaling in myeloid or cancer cells. Therefore, we examined the potential effect of paclitaxel on the activation of an inflammasome complex by examining caspase-1 activation and interleukin (IL)-1β secretion in bone marrow-derived macrophages (BMDMs). The results showed that treatment with paclitaxel alone or following LPS priming failed to trigger the secretion of active caspase-1 and IL-1β from BMDMs. However, paclitaxel could induce robust activation of caspase-1 in BMDMs in the presence of NLRP3 inflammasome-activating signal 2, such as ATP or nigericin. This paclitaxel/ATP-mediated inflammasome activation was completely abrogated in -deficient macrophages. Mechanistically, paclitaxel treatment induced robust activation of the TLR4 signaling cascade, including phosphorylation of IκB and JNK and upregulation of proinflammatory cytokine mRNA levels in a TLR4-dependent manner. In contrast, paclitaxel treatment alone did not induce mitochondrial damages such as the loss of the mitochondrial membrane potential and production of mitochondrial ROS. These findings suggest that paclitaxel can drive the priming of signal-mediated events for NLRP3 activation but not a second signal-triggered phenomenon such as mitochondrial damage. This suggestion was supported by the observations that paclitaxel treatment caused robust IL-1β production in macrophages in the presence of cell-free medium derived from growth of injured cells and also in the spleen of mice. Collectively, our data strongly indicate that paclitaxel is able to facilitate the activation of NLRP3 inflammasome signaling in a certain physiological environment.

摘要

紫杉醇是一种常用于治疗不同类型癌症的化疗药物。除了其抗肿瘤作用外,紫杉醇还已知可促进 Toll 样受体 (TLR) 4 依赖性炎症反应,这可能降低其化疗疗效。然而,目前尚不清楚紫杉醇是否能够影响髓系或癌细胞中的炎症小体信号。因此,我们通过检查 caspase-1 活化和骨髄来源的巨噬细胞 (BMDM) 中白细胞介素 (IL)-1β 的分泌来研究紫杉醇对炎症小体复合物激活的潜在影响。结果表明,紫杉醇单独处理或 LPS 引发后,未能触发 BMDM 中活性 caspase-1 和 IL-1β 的分泌。然而,在 NLRP3 炎症小体激活信号 2(如 ATP 或 Nigericin)存在的情况下,紫杉醇可诱导 BMDM 中 caspase-1 的强烈激活。这种紫杉醇/ATP 介导的炎症小体激活在 -缺陷巨噬细胞中完全被阻断。从机制上讲,紫杉醇处理以 TLR4 依赖性方式诱导 TLR4 信号级联的强烈激活,包括 IκB 和 JNK 的磷酸化以及促炎细胞因子 mRNA 水平的上调。相比之下,紫杉醇单独处理不会诱导线粒体损伤,如线粒体膜电位丧失和线粒体 ROS 的产生。这些发现表明,紫杉醇可以驱动 NLRP3 激活的信号介导事件的引发,但不是线粒体损伤等第二信号触发现象。这一观点得到了以下观察结果的支持:紫杉醇处理在来自受损细胞生长的无细胞培养基存在的情况下,以及在小鼠脾脏中,可在巨噬细胞中引起强烈的 IL-1β 产生。总之,我们的数据强烈表明,紫杉醇能够在特定生理环境中促进 NLRP3 炎症小体信号的激活。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f946/6532018/71279e7a4127/fimmu-10-01108-g0001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验